In an experimental breast cancer mouse model, doxorubicin treatment enhanced tumor antigen-specific proliferation of CD8+ T cells in tumor-draining lymph nodes and increased the infiltration of activated, interferon-γ-producing CD8+ TILs [32]. Here, CD8A is linked to breast carcinoma.